Abstract
Roche will pay Boston-based Jnana Therapeutics $40 million up front as part of a drug discovery pact that spans targets relevant in immunology and neuroscience. Stuart Schreiber and Ramnik Xavier, scientists at Broad Institute of MIT and Harvard, founded Jnana in 2017 to develop small molecules that target members of a family of 450 proteins, called solute carriers (SLC), that shuttle metabolites in and out of cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
